Toll-like receptor-mediated IRE1α activation as a therapeutic target for inflammatory arthritis
0301 basic medicine
Blotting, Western
Enzyme-Linked Immunosorbent Assay
IRE1
Protein Serine-Threonine Kinases
Real-Time Polymerase Chain Reaction
Cell Line
Arthritis, Rheumatoid
Mice
03 medical and health sciences
Drug Delivery Systems
Health Sciences
Endoribonucleases
Synovial Fluid
Animals
Immunoprecipitation
Cellular and Developmental Biology
Phosphorylation
Protein Kinase Inhibitors
Inflammation
TNF Receptor-Associated Factor 6
Gene Expression Profiling
Macrophages
Toll-Like Receptors
Ubiquitination
Molecular
3. Good health
Enzyme Activation
Cytokines
TRAF6
DOI:
10.1038/emboj.2013.183
Publication Date:
2013-08-13T14:03:35Z
AUTHORS (23)
ABSTRACT
In rheumatoid arthritis (RA), macrophage is one of the major sources of inflammatory mediators. Macrophages produce inflammatory cytokines through toll-like receptor (TLR)-mediated signalling during RA. Herein, we studied macrophages from the synovial fluid of RA patients and observed a significant increase in activation of inositol-requiring enzyme 1α (IRE1α), a primary unfolded protein response (UPR) transducer. Myeloid-specific deletion of the IRE1α gene protected mice from inflammatory arthritis, and treatment with the IRE1α-specific inhibitor 4U8C attenuated joint inflammation in mice. IRE1α was required for optimal production of pro-inflammatory cytokines as evidenced by impaired TLR-induced cytokine production in IRE1α-null macrophages and neutrophils. Further analyses demonstrated that tumour necrosis factor (TNF) receptor-associated factor 6 (TRAF6) plays a key role in TLR-mediated IRE1α activation by catalysing IRE1α ubiquitination and blocking the recruitment of protein phosphatase 2A (PP2A), a phosphatase that inhibits IRE1α phosphorylation. In summary, we discovered a novel regulatory axis through TRAF6-mediated IRE1α ubiquitination in regulating TLR-induced IRE1α activation in pro-inflammatory cytokine production, and demonstrated that IRE1α is a potential therapeutic target for inflammatory arthritis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (80)
CITATIONS (177)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....